Abstract
Antipsychotics are widely prescribed in the elderly population. Despite concern for their use, they remain frequently prescribed for psychotic symptoms and behavioral symptoms of dementia. However, the FDA has not approved any drug for treating the behavioral symptoms of dementia. There is increase in mortality risk in dementia patients with both conventional and atypical antipsychotics. In this article, we review the current evidence relative to appropriate antipsychotic use in elderly for various psychiatric disorders. Given the degree of medical comorbidity in this population, appropriate use with lowest effective dose and ongoing clinical and medical monitoring is essential in this population. If an antipsychotic is felt to be appropriate, its use should be limited to the period when the potential benefits are felt to be greater than the potential risks, and use should be restricted to the shortest time possible.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of Importance
Kuehn BM. Questionable Antipsychotic Prescribing Remains Common, Despite Serious Risks. JAMA. 2010;303(16):1582–4.
US Food and Drug Administration. Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances. Silver Spring, MD: US Food and Drug Administration; 2005. Available at: www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ ucm053171.htm . Accessed May 15 2014.
US Food and Drug Administration. FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs [news release]. Silver Spring, MD: US Food and Drug Administration; 2008. Cited June 24, 2008. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2008/ucm116912.htm.
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–84.
Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatr. 2000;157:708–14.
Wragg RE, Jeste DV. Neuroleptics and alternative treatments: Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatr Clin N Am. 1988;11:195–214.
Testad I, Aasland AM, Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):916–21.
Brodaty H, Low LF. Aggression in the elderly. J Clin Psychiatry. 2003;64:36–43.
Matsui T, Nakaaki S, Murata Y, Sato J, Shinagawa Y, Tatsumi H, et al. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale. Dement Geriatr Cogn Disord. 2006;21:182–91.
Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatry Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210–5.
Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int Psychogeriatr. 2001;13:121–8.
Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006
Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. J Am Med Assoc. 2005;293:596–608.
Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV. Pharmacologic treatment of psychosis and agitation in elderly patients with dementia: Four decades of experience. Drugs Aging. 2002;19:257–76.
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatr. 2006;14:191–210.
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525–38.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69.
Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014. doi:10.1136/jnnp-2014-308112. This is an extensive review and meta-analysis of RCTs comparing pharmacological agents with placebo onNeuropsychiatric (NPI) and safety outcomes in AD patients with neuropsychiatric symptoms.
Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of Mortality Among Individual Antipsychotics in Patients With Dementia. Am J Psychiatry. 2012;169(1):71–9.
Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321–31. This is the first study to to observe antipsychotic use and mortality in dementia outpatients over more than 6 years.
Trifiró G, Sultana J, Spina E. Are the Safety Profiles of Antipsychotic Drugs Used in Dementia the Same? An Updated Review of Observational Studies.Drug Saf. 2014 May 24. [Epub ahead of print]. This is an extensive literature review of various mortality studies comparing interdrug safety outcomes in dementia patients.
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Scneider L, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957Y970.
NICE and SCIE (2006) Dementia: Supporting People with Dementia and their Careers in Health and Social Care. NICE clinical guideline 42. Available at www.nice.org.uk/CG42
Herrmann N, Lanctôt K, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the CanadianConsensus Conference on the Diagnosis andTreatment of Dementia 2012. Alzheimers Res Ther. 2013;5 Suppl 1:S5.
Guide to the management of psychotic disorders and neuropsychiatric symptoms of dementia in older adults. American Geriatric Society Web site. Available at: http://dementia.americangeriatrics.org/GeriPsych_index.php. Accessed June 13, 2014
Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull. 1988;14:39–55.
Howard R, Castle D, Wessely S, Murray R. A comparative study of 470 cases of early and late-onset schizophrenia. Br J Psychiatry. 1993;163:352–7.
Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatry. 2000;157:172–8.
Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5–99.
Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425–33.
Almeida OP, Fenner S. Bipolar disorders: similarities and differences between patients will illness onset before and after 65 years. Int Psychogeriatr. 2002;14(3):311–22.
Young RC, Schulberg HC, Gildengers AG, Sajatovic M, Mulsant BH, Gyulai L, et al. Conceptual and methodological issues in designing a randomized controlled treatment trial for geriatric bipolar disorder: GERI-BD. Bipolar Disord. 2010;12(1):56–67.
Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics–risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11(3):113–8.
Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry. 1995;56(11):514–8.
Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008;10(6):662–71.
Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry. 2008;69(1):41–6.
Myers JK, Weissman MM, Tischler G. Six-month prevelance of psychiatric disorders in three communities. Arch Gen Psychiatry. 1984;41:959–70.
Meyers BS, Kalayam B, Mei-Tal V. Late-onset delusional depression: a distinct clinical entity? J Clin Psychiatry. 1984;45:347–9.
Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, et al. Risk of tardive dyskinesia in older patients. Arch Gen Psychiatry. 1995;52:756–65.
Janicak PG, Easton M, Comaty JE. Efficacy of ECT in psychotic and nonpsychotic depression. Convuls Ther. 1989;5:314–20.
Fann JR. The epidemiology of delirium: a review of studies and methodological issues. Sem Clin Neuropsychiatry. 2000;5:64–74.
Inouye SK. The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med. 1994;97:278–88.
Cole MG. Delirium in elderly patients. Am J Geriatr Psychiatry. 2004;12:7–21.
Inouye SK. Current concepts: delirium in older persons. N Engl J Med. 2006;354:1157–65.
Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother. 2006;40(11):1966–73.
Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics. 2002;43(3):171–4.
Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, Chapple S, Phillips B, et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res. 2010;13(5):485–90. Devlin JW, Roberts RJ.
Fong J, Skrobik Y, Riker R, Hill NS, Robbins T, Garpestad E. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010;13(2):419–27.
Yoon HJ, Park KM, Choi WJ, Choi SH, Park JY, Kim JJ, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;13:240. This is a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital.
Compliance with Ethics Guidelines
Conflict of Interest
Romika Dhar and Lou Ann Eads declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhar, R., Eads, L.A. Current Concepts Relative to the Appropriate Use of Antipsychotics in the Elderly. Curr Geri Rep 3, 253–258 (2014). https://doi.org/10.1007/s13670-014-0097-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13670-014-0097-2